VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests

SAN DIEGO, November 19 - Accumetrics, Inc., developer of the VerifyNow System, the first
point-of-care method for measuring platelet reactivity, announces that its
market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in
the POPular study, which was presented during a Late Breaking Clinical Trials
session at the American Heart Association's annual Scientific Sessions. The
VerifyNow P2Y12 Test is used to measure the antiplatelet effect of
medications, such as clopidogrel (Plavix(R)), that reduce platelet reactivity
by blocking the platelet P2Y12 receptor.

The POPular study is the first head-to-head comparison of multiple
platelet function tests in predicting adverse events in patients undergoing
elective coronary stenting. The study investigators mentioned that many of
the tests for platelet reactivity evaluated in the study are either
labor-intensive, have significant time constraints, or cannot be performed at
the point-of-care. The investigators noted that the VerifyNow System does not
have these limitations. The investigators also speculated that recent data
may soon make platelet reactivity testing a routine clinical tool.

"We are at a time when much attention has been drawn to antiplatelet
medications, such as Plavix, and understanding the variability in patients'
response to these medications. For example, patients who use certain
heartburn medications or patients with a specific genetic disposition may not
receive the desired platelet inhibiting effect of Plavix. These are only two
of the many factors that may contribute to the variability in response to
these life-saving medications. The VerifyNow P2Y12 Test can assist physicians
by providing a direct measure of the antiplatelet effect in each patient so
they can make more informed treatment decisions," said Timothy Still,
president and CEO of Accumetrics.

The VerifyNow System is widely used in various clinical settings where
antiplatelet medications are prescribed to reduce the occurrence of future
thrombotic events such as heart attack and stroke.

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic
tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform
to help physicians determine an individual's response to multiple
antiplatelet agents. Addressing every major antiplatelet drug, including
aspirin, P2Y12 inhibitors [e.g. prasugrel (Effient(TM)) and clopidogrel
(Plavix)], and GP IIb/IIIa inhibitors [e.g. abciximab (ReoPro(R)) and
eptifibatide (Integrilin(R))], the VerifyNow System provides a valuable tool
to help physicians make more informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is
a registered trademark of Sanofi-Aventis. Effient is a trademark of Eli Lilly
and Company.

    CONTACT:
    Megan Rusnack
    Lippert/Heilshorn & Associates
    +1-212-838-3777
    mrusnack@lhai.com

    Timothy I. Still
    President and CEO
    Accumetrics
    +1-858-404-8260
    press@accumetrics.com

Megan Rusnack of Lippert/Heilshorn & Associates, +1-212-838-3777, mrusnack at lhai.com, for Accumetrics, Inc.; or Timothy I. Still, President and CEO of Accumetrics, +1-858-404-8260, press at accumetrics.com